BRIEF—Expanded UK indication for CSL Seqirus' flu jab in young children

CSL Seqirus has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to extend the indication of its cell-based quadrivalent influenza vaccine (QIVc) to children aged six months and older in the UK.

With this approval, the CSL Limited-owned entity can now provide a non-egg-based vaccine option for children aged 6 months and older, for the prevention of influenza infection.

A Phase III study evaluating the immunogenicity of QIVc in children from six months of age, compared immunogenicity of QIVc with a US-licensed inactivated quadrivalent influenza vaccine (QIV) in children aged six months through 47 months.

The research showed that the vaccine was well-tolerated and had similar immune responses to QIV.